|  |
Best In-flight Health Product,
Zinopin® Long Haul is a
natural supplement with
a unique combination of
extracts comparable to a
“biochemical compression
stocking” developed and
clinically tested by Dr. John
Scurr, a leading UK surgeon
and vascular specialist, in
response to a specific market
need for a safe, natural
product to help ease the risks
associated with reduced
venous circulation efficiency
experienced by many
travellers making long haul
journeys by air, road or rail.
Zinopin® Long Haul is a high dosage
natural dietary supplement formulated
in Switzerland for long haul travel and
for anyone sitting for extended periods
of time.
Zinopin® Long Haul may help to
support vein health and blood
circulation.
Zinopin® Long Haul may help to
reduce swelling of the lower limbs
(oedema).
Zinopin® Long Haul may help to
relieve stomach “upset”.
Zinopin® Long Haul is a strong
antioxidant.
Adults and children 16 and over for
each one-way trip:
1 capsule 1 day before departure.
2 capsules at least 1 hour before
departure.
1 capsule per day for 2 days after
arrival
150mg Standardized Ginger Root
Extract
100mg Standardized French
Maritime Pine Bark Extract
In rare cases stomach discomfort maybe
experienced if taken on an empty stomach.
Important: Not recommended for use during
pregnancy or when breast feeding.
For more than 75 years
people have been travelling in
airplanes, and an association
between airline travel and
Deep Vein Thrombosis (DVT)
has been suspected for several
years. More than 10% of
passengers travelling Economy
Class are believed to suffer
from DVT. Developing DVT
after long plane flights is
often called “Economy Class
Syndrome” because seating
and leg room are particularly
cramped for passengers
in economy class. Recent
research has found that
passengers in any seating class
on planes may develop a DVT
and that any situation where
a person has limited mobility
fro a long period of time (e.g.,
a long road or rail journey,
sitting in front of computers,
etc.) may contribute to DVT.
A recent report by a French
Cardiologist Ferrarie found that
70% of travellers at risk of DVT
and who made recent journeys,
had actually travelled by car
– a much higher proportion
than those who had used train
or plane. For this reason, the
term “Traveller’s Thrombosis”
is more appropriate.
The long term consequences
of “Traveller’s Thrombosis”
are that it damages the
valves in the legs, and
reduces efficiency of the
venous circulation. This
reduced efficiency results in
progressive swelling of the
lower legs, skin discoloration,
and eventually skin ulceration.
The precise cause of Travellers Thrombosis, while
currently not clear, appear to be related, in part, to long
periods of sitting and inactivity. The decrease in activity
may lead to inadequate circulation of blood in the legs.
In addition the legs might be slightly constrained, which
could also slow down blood in the leg veins.
Other conditions which affect blood flow or normal clotting
mechanism may make some people more at risk of
developing Travellers Thrombosis.
Who is at risk?
Frequent flyers.
Women taking contraceptive pills.
People over 40.
People who have recently had surgery or an injury
(especially in the lower limbs).
People with cancer, chronic heart disease, diabetes, or
obesity.
People with cancer or history of malignancy.
People with a genetic predisposition, such as, Leiden
Factor 5.
Family history of DVT, especially under 35.
Generally, the symptoms of DVT affect only one leg.
Symptoms of DVT may include:
Swelling caused by fluid accumulation, or oedema.
Localized pain (constant or intermittent).
Tenderness.
Skin discoloration (reddishblue
or less commonly milkwhite).
Skin that’s warm to the
touch.
Low grade fever.
A tight or heavy sensation in
the leg.
Unusual firmness or
hardness in the leg.
A prominent, tender, cord like
subcutaneous vein (superficial vein).
Calf discomfort when flexing the foot
towards the knee.
However, not all DVTs
cause noticeable
symptoms. It might never
display symptoms and can
simply disappear without
you ever being aware of it
in the first place.
These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure or prevent any disease. 
|
 |
